257 related articles for article (PubMed ID: 21865375)
1. Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism.
Linglart A; Rothenbuhler A; Gueorgieva I; Lucchini P; Silve C; Bougnères P
J Clin Endocrinol Metab; 2011 Nov; 96(11):3308-12. PubMed ID: 21865375
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism.
Winer KK; Kelly A; Johns A; Zhang B; Dowdy K; Kim L; Reynolds JC; Albert PS; Cutler GB
J Pediatr; 2018 Dec; 203():391-399.e1. PubMed ID: 30470382
[TBL] [Abstract][Full Text] [Related]
3. The hypoparathyroidism of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protective effect of male sex.
Gylling M; Kääriäinen E; Väisänen R; Kerosuo L; Solin ML; Halme L; Saari S; Halonen M; Kämpe O; Perheentupa J; Miettinen A
J Clin Endocrinol Metab; 2003 Oct; 88(10):4602-8. PubMed ID: 14557429
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human parathyroid hormone (1-84) replacement therapy in a child with hypoparathyroidism.
Laurer E; Grünberger J; Naidoo U; Lanzersdorfer R; Wimleitner M; Tischlinger K; Högler W
Bone; 2021 Mar; 144():115834. PubMed ID: 33359892
[TBL] [Abstract][Full Text] [Related]
6. Treatment with rhPTH in children.
Rothenbuhler A; Linglart A
Ann Endocrinol (Paris); 2015 May; 76(2):178-9. PubMed ID: 25910999
[No Abstract] [Full Text] [Related]
7. The effect of continuous subcutaneous recombinant PTH (1-34) infusion during pregnancy on calcium homeostasis - a case report.
Ilany J; Vered I; Cohen O
Gynecol Endocrinol; 2013 Sep; 29(9):807-10. PubMed ID: 23865697
[TBL] [Abstract][Full Text] [Related]
8. Impact of periprocedural subcutaneous parathyroid hormone on control of hypocalcaemia in APS-1/APECED patients undergoing invasive procedures.
Winer KK; Schmitt MM; Ferre EMN; Fennelly KP; Olivier KN; Heller T; Lionakis MS
Clin Endocrinol (Oxf); 2021 Mar; 94(3):377-383. PubMed ID: 32955743
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
Mannstadt M; Clarke BL; Vokes T; Brandi ML; Ranganath L; Fraser WD; Lakatos P; Bajnok L; Garceau R; Mosekilde L; Lagast H; Shoback D; Bilezikian JP
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
[TBL] [Abstract][Full Text] [Related]
10. A novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, acting in a dominant fashion and strongly cosegregating with hypothyroid autoimmune thyroiditis.
Cetani F; Barbesino G; Borsari S; Pardi E; Cianferotti L; Pinchera A; Marcocci C
J Clin Endocrinol Metab; 2001 Oct; 86(10):4747-52. PubMed ID: 11600535
[TBL] [Abstract][Full Text] [Related]
11. Autosomal dominant hypoparathyroidism with severe hypomagnesemia and hypocalcemia, successfully treated with recombinant PTH and continuous subcutaneous magnesium infusion.
Sanda S; Schlingmann KP; Newfield RS
J Pediatr Endocrinol Metab; 2008 Apr; 21(4):385-91. PubMed ID: 18556971
[TBL] [Abstract][Full Text] [Related]
12. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
Clarke BL; Vokes TJ; Bilezikian JP; Shoback DM; Lagast H; Mannstadt M
Endocrine; 2017 Jan; 55(1):273-282. PubMed ID: 27734257
[TBL] [Abstract][Full Text] [Related]
13. [Hypoparathyroidism associated with autoimmune disorder].
Yamauchi M; Sugimoto T
Clin Calcium; 2007 Aug; 17(8):1193-9. PubMed ID: 17660615
[TBL] [Abstract][Full Text] [Related]
14. The autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy or autoimmune polyglandular syndrome type 1.
Lankisch TO; Jaeckel E; Strassburg CP
Semin Liver Dis; 2009 Aug; 29(3):307-14. PubMed ID: 19676003
[TBL] [Abstract][Full Text] [Related]
15. Continuous Subcutaneous Recombinant Parathyroid Hormone (1-34) Infusion in the Management of Childhood Hypoparathyroidism Associated with Malabsorption.
Saraff V; Rothenbuhler A; Högler W; Linglart A
Horm Res Paediatr; 2018; 89(4):271-277. PubMed ID: 28926829
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism.
Kim ES; Keating GM
Drugs; 2015 Jul; 75(11):1293-303. PubMed ID: 26177893
[TBL] [Abstract][Full Text] [Related]
17. Teriparatide (rhPTH) treatment in children with syndromic hypoparathyroidism.
Matarazzo P; Tuli G; Fiore L; Mussa A; Feyles F; Peiretti V; Lala R
J Pediatr Endocrinol Metab; 2014 Jan; 27(1-2):53-9. PubMed ID: 23945122
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide.
Puig-Domingo M; Díaz G; Nicolau J; Fernández C; Rueda S; Halperin I
Eur J Endocrinol; 2008 Nov; 159(5):653-7. PubMed ID: 18703565
[TBL] [Abstract][Full Text] [Related]
19. Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.
Marcucci G; Della Pepa G; Brandi ML
Expert Opin Drug Saf; 2017 May; 16(5):617-625. PubMed ID: 28332412
[TBL] [Abstract][Full Text] [Related]
20. Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.
Tuli G; Buganza R; Tessaris D; Einaudi S; Matarazzo P; de Sanctis L
Endocrine; 2020 Feb; 67(2):457-465. PubMed ID: 31705387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
